Parmax Pharma returns to positive equity of Rs 9.37 crore
Key highlights
- Parmax Pharma's total equity was Rs 9.37 crore at September 30, 2026, versus negative Rs 6.15 crore at March 31, 2026.
- Cash and cash equivalents increased to Rs 7.09 crore from Rs 0.65 crore during the half year ended September 30, 2026.
- Net financing cash inflow was Rs 15.03 crore, compared with Rs 3.81 crore in the half year ended September 30, 2025.
- The September 28, 2026 fire had a management-estimated Rs 6 crore damage figure and a Rs 4.75 crore insurance intimation.
powered by IRIS

Parmax Pharma Limited returned to positive total equity of Rs 9.37 crore at September 30, 2026, from a Rs 6.15 crore deficit at March 31, as Rs 15.03 crore of net financing inflows lifted cash and cash equivalents to Rs 7.09 crore during the half year.
Know Parmax Pharma inside out
Results, valuation, peers and who's buying, in one view.
How did Parmax Pharma return to positive equity?
Parmax Pharma returned to positive equity because equity share capital and other equity rose substantially in the half year ended September 30, 2026. Total equity moved to Rs 9.37 crore from negative Rs 6.15 crore at March 31, 2026, a Rs 15.52 crore swing in the standalone balance sheet.
Equity share capital increased to Rs 8.13 crore at September 30 from Rs 4.45 crore at March 31, while other equity moved to positive Rs 1.24 crore from negative Rs 10.60 crore. The half-year cash-flow statement recorded a Rs 3.67 crore increase in equity share capital and a Rs 11.84 crore increase in other equity.
Those capital movements were partly linked to the board-approved allotment disclosed for August 29, 2026. Parmax Pharma said it approved the allotment of 31,37,586 equity shares with a face value of Rs 10 at Rs 36.50 each, alongside 21,45,145 convertible warrants at Rs 36.50 each, with Rs 9.125 paid up per warrant.
The cash-flow statement showed net cash from financing activities of Rs 15.03 crore for the half year, after a Rs 0.49 crore decrease in other long-term borrowings. This differed from the half year ended September 30, 2025, when financing cash inflow was Rs 3.81 crore and arose from a reported increase in long-term borrowings, with no increase recorded in equity share capital or other equity.
Why did Parmax Pharma's cash balance increase?
Parmax Pharma's cash and cash equivalents increased by Rs 6.44 crore to Rs 7.09 crore in the half year ended September 30, 2026, from Rs 0.65 crore at the beginning of the financial year. Financing inflows of Rs 15.03 crore exceeded Rs 4.65 crore of operating cash use and Rs 3.94 crore used in investing activities.
Operating activities used more cash than a year earlier despite a reported pre-tax profit of Rs 2.37 crore, compared with a pre-tax loss of Rs 2.84 crore in the half year ended September 30, 2025. Net cash used in operating activities was Rs 4.65 crore in the 2026 half year, against Rs 3.34 crore used in the comparable prior-year period.
The main working-capital movements were a Rs 8.34 crore increase in trade and other receivables and a Rs 5.03 crore decrease in current liabilities. These uses were partly offset by a Rs 3.04 crore reduction in inventories and a Rs 3.57 crore decrease in short-term loans and advances.
Investing cash outflow rose to Rs 3.94 crore in the 2026 half year from Rs 0.46 crore a year earlier, entirely reported as purchases of fixed assets. Property, plant and equipment on the balance sheet increased to Rs 10.91 crore at September 30 from Rs 7.86 crore at March 31.
Got a follow-up? Ask IRIS
What changed in Parmax Pharma's assets and liabilities?
Parmax Pharma's total assets increased to Rs 38.05 crore at September 30, 2026, from Rs 28.05 crore at March 31, 2026. Current assets rose to Rs 24.85 crore from Rs 16.68 crore, while non-current assets increased to Rs 13.21 crore from Rs 11.37 crore.
Trade receivables climbed to Rs 11.51 crore at September 30 from Rs 3.16 crore at March 31, broadly matching the Rs 8.34 crore cash-flow outflow under trade and other receivables. Inventory declined to Rs 4.81 crore from Rs 7.85 crore, and current loans fell to Rs 1.08 crore from Rs 5.02 crore.
Cash was the largest change within current assets, reaching Rs 7.09 crore from Rs 0.65 crore. The balance sheet also included Rs 17.25 lakh of intangible assets under development at September 30, compared with no balance under that line at March 31.
On the funding side, non-current borrowings declined to Rs 11.03 crore from Rs 11.52 crore, consistent with the Rs 0.49 crore financing outflow for other long-term borrowings. Trade payables increased to Rs 16.90 crore from Rs 14.34 crore, while other current liabilities fell to Rs 0.51 crore from Rs 7.87 crore.
What unresolved matters affect Parmax Pharma's reported position?
Parmax Pharma had not recognised a financial-statement impact from the September 28, 2026 fire at its Hadamtala manufacturing facility as of September 30. Management was still ascertaining the loss, while the auditor cited management's estimate of Rs 6 crore in damage to property, plant and equipment and inventories.
The auditor also said Parmax Pharma had notified its insurer of Rs 4.75 crore, but no insurance claim receivable was recognised pending completion of the loss survey and the insurer's acceptance of the claim. The auditor's review conclusion was not modified in respect of this matter.
Depreciation reported for the September quarter and half year excluded depreciation on the clean-room plant and effluent treatment plant, according to Parmax Pharma. The auditor specifically drew attention to non-provision of depreciation on the effluent treatment plant during the quarter because it was not used, referring to management's assessment of useful life, residual value and recoverability.
Other income was Rs 4.33 crore in the half year ended September 30, 2026, compared with Rs 1.37 lakh a year earlier. Parmax Pharma said it wrote back Rs 2.32 crore of debt based on creditor representations and confirmations, while the auditor identified Rs 2.24 crore of long-outstanding related-party balances credited to other income during the September quarter.
The auditor's Rs 2.24 crore figure comprised Rs 1.87 crore payable for capital goods, Rs 7 lakh of a loan from Malwin Pharma Pvt. Ltd., and Rs 29 lakh of an unsecured loan from managing director Umang A. Gosalia. The auditor said the write-backs followed written waivers and approvals of the audit committee and board.
Conclusion
Parmax Pharma's return to Rs 9.37 crore of total equity reflects the Rs 15.03 crore financing inflow and the resulting increases in share capital and other equity. The balance-sheet improvement coincided with a Rs 2.37 crore half-year profit, versus a Rs 2.84 crore loss a year earlier, but operating cash flow remained negative at Rs 4.65 crore as receivables increased.
Next, the disclosed matters to watch are completion of the fire-loss survey and the insurer's decision on the Rs 4.75 crore intimation against management's Rs 6 crore damage estimate. Parmax Pharma has also left depreciation off the clean-room plant and effluent treatment plant for the reported September period, making the treatment of those assets an unresolved accounting matter.


